LION vs NBIX · rev $2.63B vs P/E 45, rev $1.77B
Lionsgate Studios Holding Corp. (to be renamed Lionsgate Studios Corp.) (LION) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Lionsgate Studios Holding Corp. (to be renamed Lionsgate Studios Corp.) (LION) is a shell companies company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported LION revenue for 2026-03-31 was $2.63B. Net income was -$198.3M. Revenue was down 17.6% from 2025-03-31 to 2026-03-31. LION currently screens at market cap $1.67B.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
LION currently screens at market cap $1.67B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the LION and NBIX stock pages for the full models.
Not investment advice.